Protagonist Therapeutics (PTGX) Gains from Investment Securities (2015 - 2020)

Protagonist Therapeutics (PTGX) reported Gains from Investment Securities of $549000.0 for Q1 2020, up 4.57% sequentially from $525000.0 in Q1 2016.

Protagonist Therapeutics (PTGX) Gains from Investment Securities (2015 - 2020) Analysis & Trends

Protagonist Therapeutics (PTGX) has 3 years of Gains from Investment Securities data on file, last reported at $549000.0 in Q1 2020.

For the quarter ending Q1 2020, Gains from Investment Securities changed N/A year-over-year to $549000.0; the trailing twelve-month figure through Mar 2020 stood at $549000.0 (changed N/A YoY), and the FY2016 full-year result was $525000.0, up 196.69% from the prior year.
Gains from Investment Securities advanced to $549000.0 in Q1 2020, from $525000.0 in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $549000.0 in Q1 2020 to a low of $525000.0 in Q1 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Protagonist Therapeutics	8.86 Bn	8.86 Bn	-

Download Data